Literature DB >> 4059858

Aseptic bone/bone marrow necrosis in leukaemia.

A Vesterby, O Myhre Jensen.   

Abstract

Aseptic (avascular) bone/bone marrow necrosis (ABN) was found in 21 leukaemic patients during a period of 14 yr, with a frequency of 6.5% in autopsied leukaemic patients, and with the highest frequency in ALL. 8 patients (38%) complained of bone pain. X-ray examination was carried out in 7 of these with a positive result in 3 (43%). Only 1 patient had elevated S-Alkaline phosphatase. Leucocytosis was found in 12 patients. Only 1 patient (ALL) received steroid in a rather high dose during 6 weeks. At autopsy ABN was found localized to the femur in all patients and 2 patients also had ABN in other bones. Post-mortem X-ray examination demonstrated changes in 8 of 15 cases (53%), with osteolysis in 6 and sclerosis in 2. 19 patients had had recent ABN with some fibroblast proliferation. In 4 of these, appositional bone formation had started. 2 patients had sclerosis as the only change. The pathogenesis of ABN is not known; an important factor, however, may be ischaemia due to vascular obstruction.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4059858     DOI: 10.1111/j.1600-0609.1985.tb01719.x

Source DB:  PubMed          Journal:  Scand J Haematol        ISSN: 0036-553X


  4 in total

1.  CRP concentration in a patient with acute leukaemia and bone marrow infarction.

Authors:  S Grützmeier; C Malm
Journal:  Med Oncol Tumor Pharmacother       Date:  1988

Review 2.  Hematologic toxicities of small molecule tyrosine kinase inhibitors.

Authors:  Nicholas A Barber; Wais Afzal; Mojtaba Akhtari
Journal:  Target Oncol       Date:  2011-11-30       Impact factor: 4.493

Review 3.  [Skeletal manifestations of systemic hematologic disorders].

Authors:  J Luitjens; A Baur-Melnyk
Journal:  Radiologe       Date:  2021-11-24       Impact factor: 0.635

4.  Avascular bone necrosis in an untreated case of chronic myelogenous leukemia.

Authors:  Z Salimi; W Vas; M Sundaram
Journal:  Skeletal Radiol       Date:  1988       Impact factor: 2.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.